Long-read sequencing has revealed that concurrent LINE-1 (L1) retrotransposition events on non-homologous chromosomes frequently generate reciprocal chromosomal translocations early in tumorigenesis, establishing retrotransposons as active drivers of structural genome evolution (1). Endogenous mechanisms that constrain L1-mediated chromosomal instability remain incompletely defined. p53 transcriptionally induces tristetraprolin (TTP/ZFP36) and let-7 microRNAs, both directly and indirectly via repression of the MYC–LIN28 oncogenic axis (2). Mature let-7 suppresses human L1 retrotransposition by binding L1 mRNA and impairing ORF2p translation (3). Here we integrate these findings into a nonlinear dynamical systems model linking p53 activation, MYC–LIN28–let-7 feedback, and L1 RNA kinetics. Deterministic analysis uncovers bistability, with a sharp p53 activation threshold separating genome-unstable (high L1) and genome-stable (low L1) attractor states. Stochastic simulations reproduce the punctuated, clustered insertion patterns observed in tumors. Modest p53 restoration disproportionately collapses burst frequency, reducing cumulative structural rearrangement burden—including reciprocal translocations—by >70% under moderate assumptions. These results reposition p53 restoration as a threshold-dependent, retrotransposon-restrictive strategy to limit early genomic diversification and clonal evolution in cancer, with implications for pharmacologic reactivation therapies.

Respiratory viruses continue to challenge global preparedness because antiviral strategies remain largely pathogen specific. RSV, SARS-CoV-2, influenza, and emerging zoonotic viruses differ genetically, yet increasing evidence suggests that they converge on a common host vulnerability: suppression of the cellular stress-response regulators p53 and NRF2. RSV promotes p53 degradation and NRF2 loss, while SARS-CoV-2 similarly impairs these pathways and amplifies inflammatory signalling. Restoration of p53 and NRF2 reactivates antiviral microRNAs, suppresses viral-entry and inflammatory pathways, restores antioxidant defences, and induces p62/SQSTM1, a broad-spectrum antiviral restriction factor. These observations suggest that host-directed therapies could complement vaccines and direct-acting antivirals by establishing a mutation-resistant layer of protection. We argue that global preparedness frameworks should formally evaluate host-directed antiviral strategies as a third pillar of pandemic readiness.